(Q35106482)

6 August 2017

1 reference

title

Will endothelin receptor antagonists have a role in heart failure? (English)

1 reference

6 August 2017

2

Thomas F Lüscher

1 reference

6 August 2017

Lukas E. Spieker

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12693734

23 December 2023

Thomas F. Lüscher

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12693734

23 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12693734

23 December 2023

publication date

1 March 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0025712502001864?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(02)00186-4

https://api.elsevier.com/content/article/PII:S0025712502001864?httpAccept=text/plain

23 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(02)00186-4

Medical Clinics of North America

23 December 2023

published in

1 reference

6 August 2017

volume

87

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

459-474

1 reference

Characterization of a coronary vasoconstrictor produced by cultured endothelial cells

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Endothelium-derived contracting factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Different Mobilization of Calcium in Endothelin-1 -Induced Contractions in Human Arteries and Veins: Effects of Calcium Antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Contribution of endogenous generation of endothelin-1 to basal vascular tone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Human pulmonary circulation is an important site for both clearance and production of endothelin-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Increased plasma concentrations of endothelin in congestive heart failure in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Plasma endothelin in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Increased endothelin in experimental heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Endothelin receptors in the failing and nonfailing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Effect of endothelin-1 on exercise-induced vasodilation in normal subjects and in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Venous endothelin receptor function in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Spontaneous endothelin production by circulating mononuclear cells from patients with chronic heart failure but not from normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Integrated cardiac, renal, and endocrine actions of endothelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Systemic and renal effects of an ET(A) receptor subtype-specific antagonist in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Reversal of postischemic acute renal failure with a selective endothelinA receptor antagonist in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Bosentan improves renal regional blood flow in rats with experimental congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Molecular and cellular biology of endothelin and its receptors--Part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Molecular and cellular biology of endothelin and its receptors--Part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Systemic Blockade of the Endothelin-B Receptor Increases Peripheral Vascular Resistance in Healthy Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Endothelin receptor antagonists inhibit endothelin in human skin microcirculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: a possible endogenous endothelin-1-mediated mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Altered expression of isoforms of myosin heavy chain mRNA in the failing rat heart is ameliorated by chronic treatment with an endothelin receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Chronic oral endothelin type A receptor antagonism in experimental heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Inhibition of myocardial endothelin pathway improves long-term survival in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Selective Endothelin-A Versus Combined Endothelin-A/Endothelin-B Receptor Blockade in Rat Chronic Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Vasodilator Effects of Endothelin-Converting Enzyme Inhibition and Endothelin ET A Receptor Blockade in Chronic Heart Failure Patients Treated With ACE Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900186-4

Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure

7 January 2021

13

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(02)00186-4

Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries

23 December 2023

36

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(02)00186-4

Vasoconstrictor effect of endothelin-1 in human skin: role of ETA and ETB receptors

23 December 2023

61

1 reference

https://api.crossref.org/works/10.1016/S0025-7125(02)00186-4

23 December 2023

Identifiers

1 reference

6 August 2017

1 reference